ACTA1 p.Glu336Ala
c.1007A>C · rs121909528 · VCV18288
ClinGen expert panel — Congenital Myopathies VCEP
Likely Pathogenic for alpha-actinopathy. Applied ACMG criteria (verbatim):
PP4_Moderate PM2_Supporting PP1_Moderate PP2 PP3
Curation rationale (ClinGen, verbatim)
The c.1007A>C (NM_001100.4(ACTA1):c.1007A>C (p.Glu336Ala)) variant in ACTA1 is a missense variant predicted to cause substitution of glutamate by alanine at amino acid 336 (p.Glu336Ala). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). ACTA1, in which the variant was identified, is defined by the ClinGen Congenital Myopathies VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). The computational predictor REVEL gives a score of 0.874, which is above the threshold of 0.7, evidence that correlates with impact to ACTA1 function (PP3). At least one patient with this variant displayed cores and fiber type disproportion on muscle biopsy, which is highly specific for actin accumulation myopathy (PP4_Moderate, PMID: 15520409). This variant has been reported in 5 individuals from one family with muscle weakness (PP1_Moderate; PMID: 15520409). In summary, this variant meets the criteria to be classified as likely pathogenic for autosomal dominant alpha-actinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen Congenital Myopathies VCEP: PM2_Supporting, PP2, PP3, PP4_Moderate, PP1_Moderate (Congenital Myopathies VCEP Specifications Version 2.0; July 8, 2024).
ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.
Computational evidence
| Protein change | ||
| AlphaMissense | 0.9878 | likely pathogenic ✓ concordant with ClinVar |
|---|---|---|
| REVEL | 0.874 | moderately pathogenic-leaning |
| SaProt | LLR -13.15 | damaging |
| ⇒ AlphaMissense, REVEL and SaProt all call this damaging. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
| Constraint at this position | ||
| Conservation | phyloP 6.1 | GERP 1.5, phastCons 1 |
| Regional constraint | o/e 0.33 | constrained · MANE · 1,613 bp · p 1.6e-54 · regional, not allelic |
| Overall | ||
| CADD | 27.2 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.
Variant & gene context
- Gene
- ACTA1
- Protein
- p.Glu336Ala
- Coding
- c.1007A>C
- MANE Select
- NM_001100
- dbSNP
- rs121909528
- Type
- single nucleotide variant
- Location
- chr1:229431626 (GRCh38)
- Gene constraint
- LOEUF 0.931 · pLI <0.01 (gnomAD)
- Structure
- AlphaFold pLDDT 95.21 · 5 PDB
- Residue 336
- a UniProt-annotated variant site (in cmyo2a)
Similar variants
- ACTA1 p.Glu336= Likely benign ★ same residue
- ACTA1 p.Glu336fs Pathogenic ★ same residue
- ACTA1 p.Glu336Asp Likely pathogenic ★ same residue
- ACTA1 c.617-5C>A Likely pathogenic ★★★ same condition
- ACTA1 c.990+1G>T Pathogenic ★★★ same condition
- ACTA1 p.Asp13Asn Likely pathogenic ★★★ same condition
- ACTA1 p.Asp290His Pathogenic ★★★ same condition
- ACTA1 p.Asp58Asn Likely pathogenic ★★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/acta1-p-glu336ala (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown